PBPK modeling: What is the role of CYP3A4 expression in the gastrointestinal tract to accurately predict first-pass metabolism?
Journal
CPT: pharmacometrics & systems pharmacology
ISSN: 2163-8306
Titre abrégé: CPT Pharmacometrics Syst Pharmacol
Pays: United States
ID NLM: 101580011
Informations de publication
Date de publication:
02 Oct 2024
02 Oct 2024
Historique:
revised:
07
09
2024
received:
16
07
2024
accepted:
18
09
2024
medline:
3
10
2024
pubmed:
3
10
2024
entrez:
3
10
2024
Statut:
aheadofprint
Résumé
Gastrointestinal first-pass metabolism plays an important role in bioavailability and in drug-drug interactions. Physiologically-based pharmacokinetic (PBPK) modeling is a powerful tool to integrate these processes mechanistically. However, a correct bottom-up prediction of GI first-pass metabolism is challenging and depends on various model parameters like the level of enzyme expression and the basolateral intestinal mucosa permeability (P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Lin JH, Lu AY. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol. 2001;41:535‐567. doi:10.1146/annurev.pharmtox.41.1.535
Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103‐141. doi:10.1016/j.pharmthera.2012.12.007
United States Food and Drug Administration. Guidance for Industry: In Vitro Drug Interaction Studies — Cytochrome P450 Enzyme‐ and Transporter‐Mediated Drug Interactions. 2020. https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/in‐vitro‐drug‐interaction‐studies‐cytochrome‐p450‐enzyme‐and‐transporter‐mediated‐drug‐interactions. Accessed October 9, 2023.
Ezuruike U, Zhang M, Pansari A, et al. Guide to development of compound files for PBPK modeling in the Simcyp population‐based simulator. CPT Pharmacomet Syst Pharmacol. 2022;11(7):805‐821. doi:10.1002/psp4.12791
Wendl T, Frechen S, Gerisch M, Heinig R, Eissing T. Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone. CPT Pharmacometrics Syst Pharmacol. 2022;11(2):199‐211. doi:10.1002/psp4.12746
Open Systems Pharmacology. https://www.open‐systems‐pharmacology.org/. Accessed October 7, 2023.
Lippert J, Burghaus R, Edginton A, et al. Open systems pharmacology community – an open access, open source, open science approach to modeling and simulation in pharmaceutical sciences. CPT Pharmacometrics Syst Pharmacol. 2019;8(12):878‐882. doi:10.1002/psp4.12473
Meyer M, Schneckener S, Ludewig B, Kuepfer L, Lippert J. Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling. Drug Metab Dispos. 2012;40(5):892‐901. doi:10.1124/dmd.111.043174
Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high‐sensitivity real‐time reverse transcription PCR. Yakugaku Zasshi. 2003;123(5):369‐375. doi:10.1248/yakushi.123.369
Nishimura M, Naito S. Tissue‐specific mRNA expression profiles of human ATP‐binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet. 2005;20(6):452‐477. doi:10.2133/dmpk.20.452
Nishimura M, Naito S. Tissue‐specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet. 2006;21(5):357‐374. doi:10.2133/dmpk.21.357
Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA‐expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol. 1999;57(5):465‐480. doi:10.1016/s0006-2952(98)00268-8
Barter ZE, Bayliss MK, Beaune PH, et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human micro‐somal protein and hepatocellularity per gram of liver. Curr Drug Metab. 2007;8(1):33‐45. doi:10.2174/138920007779315053
Cordes H, Rapp H. Gene expression databases for physiologically based pharmacokinetic modeling of humans and animal species. CPT Pharmacometrics Syst Pharmacol. 2023;12(3):311‐319. doi:10.1002/psp4.12904
Bastian FB, Roux J, Niknejad A, et al. The Bgee suite: integrated curated expression atlas and comparative transcriptomics in animals. Nucleic Acids Res. 2021;49(D1):D831‐D847. doi:10.1093/nar/gkaa793
Ohtsuki S, Schaefer O, Kawakami H, et al. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP‐glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos. 2012;40(1):83‐92. doi:10.1124/dmd.111.042259
Berggren S, Gall C, Wollnitz N, et al. Gene and protein expression of P‐glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm. 2007;4(2):252‐257. doi:10.1021/mp0600687
Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008;9(4):310‐322. doi:10.2174/138920008784220664
Niehues SM, Unger JK, Malinowski M, Neymeyer J, Hamm B, Stockmann M. Liver volume measurement: reason of the difference between in vivo CT‐volumetry and intraoperative ex vivo determination and how to cope it. Eur J Med Res. 2010;15(8):345‐350. doi:10.1186/2047-783x-15-8-345
Mcintosh RL, Anderson V. A comprehensive tissue properties database provided for the thermal assessment of a human at rest. Biophys Rev Lett. 2010;5(03):129‐151. doi:10.1142/S1793048010001184
Open Systems Pharmacology. Library of released PBPK substance models and evaluation reports. https://github.com/Open‐Systems‐Pharmacology/OSP‐PBPK‐Model‐Library. Accessed May 15, 2023.
United States Food and Drug Administration. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. 2001. https://www.fda.gov/media/70958/download. Accessed July 4, 2023.
Heikkinen AT, Baneyx G, Caruso A, Parrott N. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates ‐ an evaluation and case study using GastroPlus. Eur J Pharm Sci. 2012;47(2):375‐386. doi:10.1016/j.ejps.2012.06.013
Sim SC, Edwards RJ, Boobis AR, Ingelman‐Sundberg M. CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. Pharmacogenet Genomics. 2005;15(9):625‐631. doi:10.1097/01.fpc.0000171516.84139.89
Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. Expression of CYP3A in the human liver – evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem. 1997;247(2):625‐634. doi:10.1111/j.1432-1033.1997.00625.x
Achour B, Al‐Majdoub ZM, Grybos‐Gajniak A, et al. Liquid biopsy enables quantification of the abundance and interindividual variability of hepatic enzymes and transporters. Clin Pharmacol Ther. 2021;109(1):222‐232. doi:10.1002/cpt.2102
Grangeon A, Clermont V, Barama A, Gaudette F, Turgeon J, Michaud V. Determination of CYP450 expression levels in the human small intestine by mass spectrometry‐based targeted proteomics. Int J Mol Sci. 2021;22(23):12791. doi:10.3390/ijms222312791
Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A‐dependent metabolism. J Pharmacol Exp Ther. 1997;283(3):1552‐1562.
von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT. Cytochrome P450 3A4 and P‐glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther. 2004;75(3):172‐183. doi:10.1016/j.clpt.2003.10.008
Wenzel C, Drozdzik M, Oswald S. Mass spectrometry‐based targeted proteomics method for the quantification of clinically relevant drug metabolizing enzymes in human specimens. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1180:122891. doi:10.1016/j.jchromb.2021.122891
Yang J, Jamei M, Yeo KR, Tucker GT, Rostami‐Hodjegan A. Prediction of intestinal first‐pass drug metabolism. Curr Drug Metab. 2007;8(7):676‐684. doi:10.2174/138920007782109733
Sinha VK, Snoeys J, Osselaer NV, Peer AV, Mackie C, Heald D. From preclinical to human–prediction of oral absorption and drug‐drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example. Biopharm Drug Dispos. 2012;33(2):111‐121. doi:10.1002/bdd.1782
Achour B, Russell MR, Barber J, Rostami‐Hodjegan A. Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5′‐diphospho‐glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics. Drug Metab Dispos. 2014;42(4):500‐510. doi:10.1124/dmd.113.055632
Langenfeld E, Zanger UM, Jung K, Meyer HE, Marcus K. Mass spectrometry‐based absolute quantification of microsomal cytochrome P450 2D6 in human liver. Proteomics. 2009;9(9):2313‐2323. doi:10.1002/pmic.200800680
Dennison JB, Jones DR, Renbarger JL, Hall SD. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther. 2007;321(2):553‐563. doi:10.1124/jpet.106.118471
Westlind‐Johnsson A, Malmebo S, Johansson A, et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos. 2003;31(6):755‐761. doi:10.1124/dmd.31.6.755
Zane NR, Chen Y, Wang MZ, Thakker DR. Cytochrome P450 and flavin‐containing monooxygenase families: age‐dependent differences in expression and functional activity. Pediatr Res. 2018;83(2):527‐535. doi:10.1038/pr.2017.226
Miyauchi E, Tachikawa M, Decleves X, et al. Quantitative atlas of cytochrome P450, UDP‐glucuronosyltransferase, and transporter proteins in jejunum of morbidly obese subjects. Mol Pharm. 2016;13(8):2631‐2640. doi:10.1021/acs.molpharmaceut.6b00085
Wegler C, Wisniewski JR, Robertsen I, et al. Drug disposition protein quantification in matched human jejunum and liver from donors with obesity. Clin Pharmacol Ther. 2022;111(5):1142‐1154. doi:10.1002/cpt.2558
Wolbold R, Klein K, Burk O, et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology. 2003;38(4):978‐988. doi:10.1053/jhep.2003.50393
Tantcheva‐Poór I, Zaigler M, Rietbrock S, Fuhr U. Estimation of cytochrome P‐450 CYP1A2 activity in 863 healthy Caucasians using a saliva‐based caffeine test. Pharmacogenetics. 1999;9(2):131‐144.
Scherf‐Clavel M, Deckert J, Menke A, Unterecker S. Smoking is associated with lower dose‐corrected serum concentrations of escitalopram. J Clin Psychopharmacol. 2019;39(5):485‐488. doi:10.1097/JCP.0000000000001080
Galetin A, Gertz M, Houston JB. Potential role of intestinal first‐pass metabolism in the prediction of drug‐drug interactions. Expert Opin Drug Metab Toxicol. 2008;4(7):909‐922. doi:10.1517/17425255.4.7.909
Galetin A, Gertz M, Houston JB. Contribution of intestinal cytochrome p450‐mediated metabolism to drug‐drug inhibition and induction interactions. Drug Metab Pharmacokinet. 2010;25(1):28‐47. doi:10.2133/dmpk.25.28
Galetin A, Hinton LK, Burt H, Obach RS, Houston JB. Maximal inhibition of intestinal first‐pass metabolism as a pragmatic indicator of intestinal contribution to the drug‐drug interactions for CYP3A4 cleared drugs. Curr Drug Metab. 2007;8(7):685‐693. doi:10.2174/138920007782109805
Galetin A, Houston JB. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first‐pass metabolism. J Pharmacol Exp Ther. 2006;318(3):1220‐1229. doi:10.1124/jpet.106.106013
Zhang X, Yang Y, Grimstein M, et al. Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: an update on the 2018–2019 submissions to the US FDA's Office of Clinical Pharmacology. J Clin Pharmacol. 2020;60(Suppl 1):S160‐S178. doi:10.1002/jcph.1767
Edginton AN, Theil FP, Schmitt W, Willmann S. Whole body physiologically‐based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol. 2008;4(9):1143‐1152. doi:10.1517/17425255.4.9.1143
Frechen S, Solodenko J, Wendl T, et al. A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4‐mediated drug‐drug interactions. CPT Pharmacometrics Syst Pharmacol. 2021;10(6):633‐644. doi:10.1002/psp4.12636